18th Annual Conference on Hypertension, Diabetes and Dyslipidemia

June 27-29, 2014

Jan Basile, MD, FACP, FASH
Professor of Medicine

Seinsheimer Cardiovascular Health Program

Division of General Internal Medicine

Medical University of South Carolina

Ralph H Johnson VA Medical Center

Charleston, SC

Jan N. Basile MD, FACP, FASH completed his medical degree at the Medical College of Virginia in Richmond. He served his internship and residency at the Medical University of South Carolina in Charleston, where he was also Chief Resident. He is boarded in internal medicine and is a Fellow of the American College of Physicians (FACP) and the American Society of Hypertension (FASH), as well as a member of the ASH Board of Directors. His many honors and awards include the Medical University of South Carolina School of Medicine Excellence in Teaching Award and the Golden Apple awards.

Dr. Basile’s research interests include outcome-based studies involving hypertension, lipid disorders, and diabetes. He has been involved in many large hypertension trials including the ALLHAT, ACCORD, ONTARGET, ACCOMPLISH, and VALUE trials and is currently participating in SPRINT, under the auspices of the National Heart, Lung, and Blood Institute. In addition to his contributing to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Dr. Basile has published more than 300 original papers, abstracts, editorials, and book chapters, as well as a textbook, Hot Topics: Hypertension (Hanley & Belfus, 2003).

 

Norman M. Kaplan, MD
Clinical Professor of Medicine
The University of Texas Southwestern Medical Center
Dallas, Texas
 

Dr. Kaplan is Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical Center at Dallas where he has been on the faculty for more than forty years.  For the last twenty, his teaching, writing and research have focused primarily upon clinical aspects of hypertension.  He has lectured extensively and contributed over 500 papers to the medical literature.  The tenth edition of his textbook, Kaplan’s Clinical Hypertension, was published in early 2010 .  He was a member of the third, fourth, fifth, and sixth Joint National Committees on Detection, Evaluation and Treatment of High Blood Pressure.  He has been made a Master of the American College of Physicians, given the Lifetime Achievement Award by the American Heart Association’s Council for High Blood Pressure Research, and received the Stevo Julius Award for Leadership in Medical Communication presented by the International Society of Hypertension. He served on the Executive Committees of the American Society of Hypertension and the AHA Council for High Blood Pressure Research. He is involved as either editor or reviewer with most of the journals which publish papers in the hypertension arena.

 

 

Brent M. Egan, MD

Professor of Medicine

University of South Carolina School of Medicine, Greenville

Greenville Health System

Medical Director, Care Coordination Institute

Greenville, SC

Brent M. Egan, MD received his medical degree and training in medicine and hypertension at the University of Michigan.  His research interests have centered on metabolic syndrome and mechanisms of obesity-associated hypertension and vascular disease as well as key drivers of clinical outcomes in primary care.  Dr. Egan serves on editorial boards for 8 journals and has published >250 original papers and reviews in the field of hypertension, cardiovascular disease and health disparities.  He also serves as President of the International Society of Hypertension in Blacks and American Society of Hypertension Specialists Program.

In 1999 Dr. Egan started the Outpatient Quality Improvement Network (OQUIN) Hypertension Initiative to collaborate with primary care physicians in South Carolina and beyond to optimize control of modifiable CV risk factors and reduce CV morbidity and mortality.  When Dr Egan moved from Charleston in 2013, OQUIN transitioned to the Care Coordination Institute in Greenville, now working with ~450 primary care practices with ~2 million patients.  These practices are meeting and exceeding 2017 standards of the Centers for Disease Control’s Million Hearts Program.  Under his leadership, South Carolina has improved from 50th in CV mortality among states in the U.S. to 34th in 2009.  While progress has been made, Dr. Egan remains committed to working collaboratively with colleagues locally, regionally, nationally and internationally to realize greater benefits of evidence-based medicine.

 

Peter P. Toth, MD, PhD

Director of Preventative Cardiology
CGH Medical Center
Sterling, Illinois

Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine

Peoria, Illinois
Professor of Clinical Medicine

Michigan State University College of Osteopathic Medicine
East Lansing, Michigan

Dr. Toth received his B.A. in Biochemistry from Princeton University and a Ph.D. in Biochemistry from Michigan State University. He graduated from Wayne State University School of Medicine and completed residency training in Family Medicine at the University of Iowa Hospitals and Clinics. Dr. Toth is a member of the American College of Cardiology Foundation Council on Cardiovascular Disease Prevention and the American Heart Association’s Council on Lipoproteins, Lipid Metabolism, and Thrombosis. He is a member of Alpha Omega Alpha and Sigma Xi, and is Immediate Past President of the National Lipid Association. Dr. Toth is Vice President of the American Board of Clinical Lipidology and a member of the board of the American Society of Preventive Cardiology.

Dr. Toth has authored and coauthored over two hundred twenty publications in medical and scientific journals and textbooks. He is Editor-in-Chief of the Year in Lipid Disorders (Atlas Publishing, Oxford, UK) and an Associate Editor for the Year Book of Endocrinology (Elsevier, New York). He is coeditor with Antonio Gotto of the textbook, Comprehensive Management of High Risk Cardiovascular Patients (Taylor and Francis, New York) with Michael Davidson of Therapeutic Lipidology (Humana, Philadelphia), with Dominic Sica of Current Controversies in Dyslipidemia Management (Atlas Publishing, Oxford), with Kevin Maki of Practical Lipid Management (Wiley-Blackstone, London), with Christopher Cannon of Comprehensive Cardiovascular Care in the Primary Care Setting (Springer Humana, Philadelphia), Domenic Sica of Clinical Challenges in Hypertension vols I and II (Clinical Publishing, Oxford, UK), Cardiac Lipoglucotoxicity with Vasu Raghavan, and Lipoproteins in Diabetes Mellitus with Alicia Jenkins and Timothy Lyons.. He has lectured on many topics in cardiovascular medicine throughout the world.

 

Sergio Fazio, MD, Ph
Cornelius Vanderbilt Chair of Cardiovascular Medicine
Professor of Medicine and
of Pathology, Immunology and Microbiology
Chief, Section of Cardiovascular Disease Prevention
Vanderbilt University Medical Center

Nashville, Tennessee

A graduate of the medical school in Rome, Italy where he also did his metabolic disease fellowship  training , Dr. Fazio came to UCSF as an Instructor in medicine where he completed his Ph.D. He has been at Vanderbilt University since 1993 first in Endocrinology and since 1999 in Cardiology where he is the chief of CV disease prevention. Dr Fazio's interest in CV disease prevention spans the range from molecular to population studies. His work has contributed to our understanding of lipoprotein assembly and clearance, HDL biogenesis, and the pathogenesis of genetic dyslipidemias. He has defined the role for macrophages in atherogenesis, and has identified molecular messengers that transduce metabolic signals to aggravate arterial plaque formation and progression. As a clinician, he focuses on genetic dyslipidemias and on severe secondary dyslipidemias. He has published over 180 papers, including original articles, reviews, editorials, and book chapters.

Hertzel Gerstein, MD MSc FRCPC
Professor, Departments of Medicine and Clinical Epidemiology and Biostatistics
Population Health Institute Chair in Diabetes Rese

Director, Division of Endocrinology & Metabolism
Director, Diabetes Care and Research Program

Deputy Director, Population Health Research Institute
McMaster University and Hamilton Health Sciences

Hamilton, Ontario, Canada

An Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, Dr Gerstein holds the Population Health Institute Chair in Diabetes Research. He is also Director of the Division of Endocrinology & Metabolism, Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute. He pioneered the importance of large outcomes trials in people with diabetes, and has led or co-led many such trials globally (including HOPE, ACCORD, DREAM, TIDE, ORIGIN, REWIND, and ELIXA). He has published more than 300 papers, editorials and commentaries, mainly on diabetes-related issues. Honors include the Canadian Diabetes Association’s Young Scientist Award (1999), Frederick G. Banting award (1999), Charles H. Best award (2007), and Lifetime Achievement Award (2012).

 

Richard M. Bergenstal, MD
Clinical Professor, Department of Medicine
University of Minnesota

Executive Director
International Diabetes Center at Park Nicollet

Minneapolis, MN
 

A graduate of the University of Florida with a BS in chemistry, Dr Bergenstal attended the University of Chicago Pritzker School of Medicine where he also did his internal medicine and endocrinology training. He was on the faculty there for several years and has had a distinguished career as a research clinician at the International Diabetes Center (IDC) at Park Nicollet in Minneapolis where he is the Executive Director. He cares for patients enrolled in studies related to type 1 and type 2 diabetes, especially as it relates to new diabetes technology. A Past President of the American Diabetes Association, he has received many professional honors and awards involving the training of physicians and developing diabetes educational materials for both patients and physicians. Widely published, he has been involved in most of the seminal clinical trials in diabetes including the Diabetes Control and Complications Trial (DCCT), its follow-up study Epidemiology of Diabetes Interventions and Complications (EDIC), Action to Control Cardiovascular Risk in Diabetes (ACCORD) and most recently the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Donald J. DiPette, MD, FACP, FAHA
Distinguished Professor of Health Sciences                                                  
Special Assistant to the Provost for Health Affairs 
University of South Carolina School of Medicine
Columbia, South Carolina

Dr. DiPette graduated with a Bachelor’s degree from Seton Hall and an MD from Pennsylvania State University. After completing his training in internal medicine and hypertension at Boston University School of Medicine, he joined the University of Pittsburgh, where he held joint appointments in the School of Medicine and the School of Public Health. He directed the Internal Medicine Residency Program and the Hypertension Research Program at Allegheny General Hospital during his tenure at Pittsburgh. From 1986 - 1999, he served at the University of Texas Medical Branch in Galveston  as director of the Division of General Internal Medicine, as director of the Hypertension Section and as vice chairman for both educational affairs and inpatient affairs within the department of medicine.

In 1999, he was named chairman and professor in the department of medicine in the College of Human Medicine at Michigan State University, where he remained until joining Texas A&M in 2002. There he was chairman and professor of the department of medicine at the Texas A&M Health Sciences Center, College of Medicine, and Scott & White Health System. Most recently, he has been Dean of the University of South Carolina School of medicine.  He is board certified in internal medicine and clinical pharmacology and has a specialist certification in hypertension. His major areas of research, which have been funded consistently by the American Heart Association and the National Institutes of Health, include the pharmacologic treatment of hypertension and the role of novel neuropeptides in the pathophysiology of hypertension. He has published more than 120 manuscripts in leading peer-reviewed clinical and basic science journals.